Other News To Note
Wednesday, April 17, 2013
Innate Pharma SA, of Marseille, France, reported preclinical data for two of its programs. For its IPH33 program, it reported that humanized anti-TLR3 antibodies showed efficient blocking of TLR3 signaling with high potency.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.